PIG-G Inhibitors
PIG-G inhibitors are a class of chemical compounds that specifically target and inhibit the enzyme PIG-G, which stands for phosphatidylinositol glycan anchor biosynthesis class G. This enzyme plays a critical role in the biosynthetic pathway that produces glycosylphosphatidylinositol (GPI) anchors. GPI anchors are complex glycolipids that attach to the C-terminus of proteins and facilitate their attachment to the cell membrane. The process of anchoring proteins to the cell membrane is essential for a variety of cellular functions, as it helps to localize and stabilize proteins on the cellular surface. PIG-G functions at a distinct step within the GPI anchor biosynthesis pathway, catalyzing a necessary reaction that contributes to the proper assembly of GPI anchors. The inhibition of PIG-G disrupts this pathway, leading to a number of downstream effects on cellular processes due to the improper anchoring of proteins.
The chemical structure of PIG-G inhibitors is often complex, reflecting the need to specifically interact with the active site of the PIG-G enzyme. These compounds are typically the result of targeted medicinal chemistry efforts, designed to fit within the enzyme's active site and competitively inhibit the binding of natural substrates. The specificity of PIG-G inhibitors is crucial, as it ensures minimal off-target effects on other enzymes within the GPI anchor biosynthesis pathway or other unrelated biological pathways. The design of PIG-G inhibitors is informed by a deep understanding of the enzyme's structure and the molecular mechanics of its action. Structural biology techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy are often employed to unravel the three-dimensional configuration of the enzyme, which aids in the rational design of these inhibitors. The development of PIG-G inhibitors is a testament to the advancements in the field of chemical biology and the ability to manipulate highly specific cellular processes through small molecule interventions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation in the ER, which is essential for proper folding and stability of many proteins. By disrupting this process, it indirectly affects the stability and function of PIG-G, which is a GPI-anchor biosynthesis enzyme, reliant on glycosylation for its activity. | ||||||
Benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside | 3554-93-6 | sc-203427 sc-203427A | 100 mg 1 g | $350.00 $3184.00 | 2 | |
This compound is a competitive inhibitor of α-Galactosidase, which may interfere with the glycosylation process critical for PIG-G. By hindering proper glycosylation, the compound can indirectly decrease the functional activity of PIG-G. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine is an inhibitor of Golgi alpha-mannosidase II, an enzyme involved in trimming mannose residues during N-glycan maturation. This disruption can lead to misfolded glycoproteins, potentially affecting the stability and function of PIG-G. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine is a glucosidase inhibitor that blocks the trimming of glucose residues in the ER, a step in glycoprotein maturation. Such inhibition could lead to improper folding and function of PIG-G, which requires proper glycosylation. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
Deoxymannojirimycin inhibits mannosidase I in the ER and Golgi apparatus, which is crucial for N-glycan processing. This inhibition can result in defective glycoprotein processing, potentially impairing PIG-G activity. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Deoxynojirimycin inhibits glucosidase I and II, enzymes necessary for N-glycan processing. By blocking these enzymes, the chemical could lead to misfolded proteins and indirectly reduce PIG-G activity. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the function of the Golgi apparatus, impeding protein trafficking and glycosylation. This disruption can indirectly affect PIG-G, which relies on the Golgi for proper processing and function. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is an ionophore that disrupts Golgi function by altering pH and cation gradients. This disruption can affect glycosylation and trafficking of proteins, potentially leading to a decrease in PIG-G function. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine is a mannosidase I inhibitor that impairs N-glycan processing in the ER. By inhibiting this process, it could indirectly lead to the decreased activity of PIG-G, which is involved in glycoprotein synthesis. | ||||||
N-Butyldeoxynojirimycin·HCl | 210110-90-0 | sc-201398 sc-201398A sc-201398B | 5 mg 25 mg 50 mg | $180.00 $550.00 $985.00 | 4 | |
N-butyldeoxynojirimycin inhibits glucosidase I and II, necessary for the proper processing of N-glycans. This inhibition may result in improperly folded glycoproteins and indirectly impact the activity of PIG-G. | ||||||